Argen-X (ARGX.BR) — Quality & forensics
As of 2026-10-13 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 29
- Quality 75
- Growth 90
- Balance sheet 95
- Cash quality 39
- Capital allocation 18
- Momentum 53
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — above the −1.78 threshold the literature flags for earnings-manipulation risk. A screen, not an accusation.
Continue: the ARGX.BR chart & overview
FAQ · from the current data · as of 2026-10-13
Quick answers
What is Argen-X's Closelooknet quality reading?
The composite reads 63/100 across 7 modules, as of 2026-10-13: valuation 29, quality 75, growth 90, balance sheet 95, cash quality 39, capital allocation 18, momentum 53. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Argen-X's Altman Z-Score?
21.54, which sits in the safe zone (above 2.99) as of 2026-10-13. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Argen-X's Piotroski F-Score?
5 of 8, as of 2026-10-13. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Argen-X's Beneish M-Score indicate?
-1.44 — above the −1.78 threshold the literature flags for earnings-manipulation risk, as of 2026-10-13. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ONC BeiGene, Ltd.industry
- ARGX argenx NV ADRindustry
- KRYS Krystal Biotech Incindustry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- MRNA Moderna Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- CAI Caris Life Sciences, Inc. Common Stockindustry
- RXRX Recursion Pharmaceuticals Incindustry
- EXEL Exelixis Incindustry
- TWST Twist Bioscience Corpindustry
- TECH Bio-Techne Corpindustry
- RPRX Royalty Pharma Plcindustry
- BION.SW BB Biotech AGindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- INCY Incyte Corporationindustry
- GNS.L Genus PLCindustry
- APLS Apellis Pharmaceuticals Incindustry